Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism by Ho Jin Kim, Orhan Aktas, Kristina R. Patterson, Schaun Korff, Amy Kunchok, Jeffrey L. Bennett, Brian G. Weinshenker, Friedemann Paul, Hans‐Peter Hartung, Daniel Cimbora, Michael A. Smith, Nanette Mittereder, William A. Rees, Dewei She, Bruce A. C. Cree

Get full text